FNY Partners Fund’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

FNY Partners Fund’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-500	Closed	-$34K	–	1185
2017 Q1	$34K	Buy	+500	New	+$33.6K	﹤0.01%	828

Other funds holding XBI

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

QIM

Quantitative Investment Management Charlottesville, Virginia $917M AUM 3.96% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

AssetMark Inc Concord, California $58.2B AUM 22.78% 1-Year Est. Return

FNY Partners Fund's XBI Position: Q2 2017 in Review

FNY Partners Fund sold out of State Street SPDR S&P Biotech ETF (XBI) in Q2 2017, closing a stake of 500 shares — an estimated $34K sold.

FNY Partners Fund first reported a position in XBI in Q1 2017 and held it in 1 quarter. The position peaked at $34K in Q1 2017. 314 funds tracked by Wall St. Rank hold XBI as of Q2 2017.

FNY Partners Fund reported no remaining State Street SPDR S&P Biotech ETF position as of Q2 2017 after selling out during the quarter.
FNY Partners Fund sold 500 State Street SPDR S&P Biotech ETF shares in Q2 2017, an estimated $34K.
FNY Partners Fund first reported a position in State Street SPDR S&P Biotech ETF in Q1 2017 and held it in 1 quarter.
FNY Partners Fund's State Street SPDR S&P Biotech ETF position peaked at $34K in Q1 2017.
314 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2017.

Based on FNY Partners Fund's 13F filing for Q2 2017, filed 10 Aug 2017.